Mutations within the TNF-like core domain of RANKL impair osteoclast differentiation and activation

Molecular Endocrinology

Volumn 23, Issue 1, 2009, Pages 35-46

  Cheng, Taksum ^a   Pavlos, Nathan J ^a   Wang, Cathy ^a   Tan, Jamie We Yin ^a   Lin, Jian Ming ^b   Cornish, Jillian ^b   Zheng, Ming Hao ^a   Xu, Jiake ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR; TUMOR NECROSIS FACTOR;

ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE DELETION; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTATION; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; WILD TYPE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; BASE SEQUENCE; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE; DNA PRIMERS; HUMANS; I-KAPPA B PROTEINS; MAP KINASE SIGNALING SYSTEM; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NF-KAPPA B; OSTEOCLASTS; OSTEOPETROSIS; PROTEIN STRUCTURE, TERTIARY; RANK LIGAND; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; SEQUENCE DELETION; SIGNAL TRANSDUCTION;

EID: 58149250542     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2007-0465     Document Type: Article

References (35)

1. Teitelbaum SL 2000 Bone resorption by osteoclasts. Science 289:1504-1508
2. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179
3. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176
4. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett III FS, Frankel WN, Lee SY, Choi Y 1997 TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272:25190-25194
5. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602
6. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323
7. Wong BR, Josien R, Choi Y 1999 TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol 65:715-724
8. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM 2000 The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103:41-50
9. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T, Penninger JM 2006 Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:692-696
10. Huang L, Xu J, Wood DJ, Zheng MH 2000 Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-κB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 156:761-767
11. Liu D, Xu JK, Figliomeni L, Huang L, Pavlos NJ, Rogers M, Tan A, Price P, Zheng MH 2003 Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. Int J Mol Med 11:17-21
12. Laird RK, Pavlos NJ, Xu J, Brankov B, White B, Fan Y, Papadimitriou JM, Wood DJ, Zheng MH 2006 Bone allograft non-union is related to excessive osteoclastic bone resorption: a sheep model study. Histol Histopathol 21:1277-1285
13. Roux S, Meignin V, Quillard J, Meduri G, Guiochon-Mantel A, Fermand JP, Milgrom E, Mariette X 2002 RANK (receptor activator of nuclear factor-κB) and RANKL expression in multiple myeloma. Br J Haematol 117:86-92
14. Hamdy NA 2008 Denosumab: RANKL inhibition in the management of bone loss. Drugs Today (Barc) 44:7-21
15. Xu J, Wu HF, Ang FS, Yip K, Woloszyn M, Zheng MH, Tan RX 27 November 2008 NF-κB modulators in osteolytic bone diseases. Cytokine Growth Factor Rev, Epub ahead of print
16. Xu J, Tan JW, Huang L, Gao XH, Laird R, Liu D, Wysocki S, Zheng MH 2000 Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-κB ligand. J Bone Miner Res 15:2178-2186
17. Lam J, Nelson CA, Ross FP, Teitelbaum SL, Fremont DH 2001 Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest 108:971-979
18. Ito S, Wakabayashi K, Ubukata O, Hayashi S, Okada F, Hata T 2002 Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution. J Biol Chem 277:6631-6636
19. Sobacchi C, Frattini A, Guerrini MM, Abinun M, Pangrazio A, Susani L, Bredius R, Mancini G, Cant A, Bishop N, Grabowski P, Del Fattore A, Messina C, Errigo G, Coxon FP, Scott DI, Teti A, Rogers MJ, Vezzoni P, Villa A, Helfrich MH 2007 Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 39:960-962
20. Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB 1998 Characterization of the intracellular domain of receptor activator of NF-κB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-κB and c-Jun N-terminal kinase. J Biol Chem 273:20551-20555
21. Galibert L, Tometsko ME, Anderson DM, Cosman D, Dougall WC 1998 The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-κB, a member of the TNFR superfamily. J Biol Chem 273:34120-34127
22. Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH, Xu J 2003 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-κB activation. J Bone Miner Res 18:2159-2168
23. Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y 2001 Tumor necrosis factor-α (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 276:563-568
24. Partidos CD, Steward MW 2002 Mimotopes of viral antigens and biologically important molecules as candidate vaccines and potential immunotherapeutics. Comb Chem High Throughput Screen 5:15-27
25. Partidos CD, Chirinos-Rojas CL, Steward MW 1997 The potential of combinatorial peptide libraries for the identification of inhibitors of TNF-α mediated cytotoxicity in vitro. Immunol Lett 57:113-116
26. Aoki K, Saito H, Itzstein C, Ishiguro M, Shibata T, Blanque R, Mian AH, Takahashi M, Suzuki Y, Yoshimatsu M, Yamaguchi A, Deprez P, Mollat P, Murali R, Ohya K, Horne WC, Baron R 2006 A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. J Clin Invest 116:1525-1534
27. Ikeda T, Kasai M, Suzuki J, Kuroyama H, Seki S, Utsuyama M, Hirokawa K 2003 Multimerization of the RANKL isoforms and regulation of osteoclastogenesis. J Biol Chem 278:1525-1534
28. Yip KH, Feng H, Pavlos NJ, Zheng MH, Xu J 2006 p62 ubiquitin binding-associated domain mediated the receptor activator of nuclear factor-κB ligand-induced osteoclast formation: a new insight into the pathogenesis of Paget's disease of bone. Am J Pathol 169:503-514
29. Ang ES, Zhang P, Steer JH, Tan JW, Yip K, Zheng MH, Joyce DA, Xu J 2007 Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor κ B ligand (RANKL). J Cell Physiol 212:787-795
30. Akama KT, Albanese C, Pestell RG, Van Eldik LJ 1998 Amyloid β-peptide stimulates nitric oxide production in astrocytes through an NFκB-dependent mechanism. Proc Natl Acad Sci USA 95:5795-5800
31. Steer JH, Kroeger KM, Abraham LJ, Joyce DA 2000 Glucocorticoids suppress tumor necrosis factor-α expression by human monocytic THP-1 cells by suppressing transactivation through adjacent NF-κB and c-Jun-activating transcription factor-2 binding sites in the promoter. J Biol Chem 275:18432-18440
32. Rea SL, Walsh JP, Ward L, Yip K, Ward BK, Kent GN, Steer JH, Xu J, Ratajczak T 2006 A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-κB signaling and Paget's disease of bone with a severe phenotype. J Bone Miner Res 21:1136-1145
33. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL 1999 The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527-538
34. Hakeda Y, Kobayashi Y, Yamaguchi K, Yasuda H, Tsuda E, Higashio K, Miyata T, Kumegawa M 1998 Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. Biochem Biophys Res Commun 251:796-801
35. Middleton-Hardie C, Zhu Q, Cundy H, Lin JM, Callon K, Tong PC, Xu J, Grey A, Cornish J, Naot D 2006 Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL. J Bone Miner Res 21:438-445